Immunoglobulin use in childhood epilepsy
Literature review
Keywords:
Epilepsy, Immunoglobulin, PediatricsAbstract
Background: Epilepsy's aetiology is well-known to include an immune component. Several clinical and laboratory research have discovered abnormalities in epileptic patients' immune system branches when compared to the general population. Such anomalies include immunoglobulin deficiencies (mainly immunoglobulin A and immunoglobulin G2), an increased prevalence of specific human leukocyte antigen types, and alterations in cytokine and interleukin profiles. In people with epilepsy, autoantibodies were discovered against glutamic acid decarboxylase, components of the voltage-gated potassium channel complex, and the N-methyl-D-aspartate, gamma-aminobutyric acid, a-amino-3-hydroxy-5-methyl-4 isoxazolepropionic acid, and glutamate receptor three receptors. Immune modulating drugs like corticosteroids and corticotrophin have also been demonstrated to help with seizures. In view of these findings, immunosuppressive medicine has potential as an add-on therapy for refractory epilepsy. Aim: We aimed to evaluate the efficacy of immunoglobulin in childhood epilepsy. Conclusion: Despite the fact that new medications are constantly being developed to treat intractable infantile epilepsy, the refractory rate remains high. Despite several investigations on the subject, predictive variables for a good intravenous immunoglobulin response have yet to be identified. In some epileptic disorders, such as idiopathic West syndrome and electrical status epilepticus during sleep, intravenous immunoglobulin appears to be beneficial.
Downloads
References
Billiau AD, Wouters CH, Lagae LG. Epilepsy and the immune system: Is there a link? Eur J Paediatr Neurol 2005;9:29e42.
Hrachovy RA, Frost JD Jr, Pollack MS, Glaze GD. Serologic HLA typing in infantile spasms. Epilepsia 1988;29:817e9.
Pacifici R, Paris L, Di Carlo S, Bacosi A, Pichini S, Zuccaro P. Cytokine production in blood mononuclear cells from epileptic patients. Epilepsia 1995;36:384e7.
Peltola J, Palmio J, Korhonen L, et al. Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures. Epilepsy Res 2000;41:205e11.
Vezzani A, Balosso S, Ravizza T. The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun 2008;22:797e803.
Irani SR, Bien CG, Lang B. Autoimmune epilepsies. Curr Opin Neurol 2011; 24:146e53.
Bien CG, Scheffer IE. Autoantibodies and epilepsy. Epilepsia 2011;52(Suppl. 3):18e22.
Aarli JA. Epilepsy and the immune system. Arch Neurol 2000;57:1689e92.
Finberg RW, Newburger JW, Mikati MA, Heller AH, Burns JC. Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood. J Pediatr 1992;120:376e80.
Emmi L, Chiarini F. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci 2002;23(Suppl. 1): 1e8.
Péchadre JC, Sauvezie B, Osier C, Gibert J. The treatment of epileptic encephalopathies with gamma globulin in children [in French]. Rev Electro- encephalogr Neurophysiol Clin 1977;7:443e7.
Engel J Jr, International League Against Epilepsy. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: Report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42: 796e803.
Billiau AD, Witters P, Ceulemans B, Kasran A, Wouters C, Lagae L. Intravenous immunoglobulins in refractory childhood-onset epilepsy: Effects on seizure frequency, EEG activity, and cerebrospinal fluid cytokine profile. Epilepsia 2007;48:1739e49.
Mikati MA, Kurdi R, El-Khoury Z, Rahi A, Raad W. Intravenous immunoglob- ulin therapy in intractable childhood epilepsy: Open label study and review of the literature. Epilepsy Behav 2010;17:90e4.
Geng J, Dong J, Li Y, Ni H, Jiang K, Shi LL, Wang G. Intravenous immuno- globulins for epilepsy. Cochrane Database Syst Rev 2011;19:CD008557.
van Rijckevorsel-Harmant K, Delire M, Schmitz-Moorman W, Wieser HG. Treatment of refractory epilepsy with intravenous immunoglobulins: Results of the first double-blind/dose finding clinical study. Int J Clin Lab Res 1994;24: 162e6.
Leach JP, Chadwick DW, Miles JB, Hart IK. Improvement in adult-onset Rasmussen’s encephalitis with long-term immunomodulatory therapy. Neurology 1999;52:738e42.
Villani F, Spreafico R, Farina L, et al. Positive response to immunomodulatory therapy in an adult patient with Rasmussen’s encephalitis. Neurology 2001;56:248e50.
Hart YM, Cortez M, Andermann F, et al. Medical treatment of Rasmussen’s syndrome (chronic encephalitis and epilepsy): Effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 1994;44:1030e6.
Granata T, Fusco L, Gobbi G, et al. Experience with immunomodulatory treatments in Rasmussen’s encephalitis. Neurology 2003;61:1807e10.
Fayad MN, Choueiri R, Mikati M. Landau-Kleffner syndrome: Consistent response to repeated intravenous gamma-globulin doses: A case report. Epilepsia 1997;38:489e94.
Lagae LG, Silberstein J, Gillis PL, Casaer PJ. Successful use of intravenous immunoglobulins in Landau-Kleffner syndrome. Pediatr Neurol 1998;18: 165e8.
Mikati MA, Saab R. Successful use of intravenous immunoglobulin as initial monotherapy in Landau-Kleffner syndrome. Epilepsia 2000;41:880e6.
Arts WF, Aarsen FK, Scheltens-de Boer M, Catsman-Berrevoets CE. Landau- Kleffner syndrome and CSWS syndrome: Treatment with intravenous immunoglobulins. Epilepsia 2009;50(Suppl. 7):55.
Nevsimalova S, Tauberova A, Doutlik S, Kucera V, Dlouhá O. A role of autoimmunity in the etiopathogenesis of Landau-Kleffner syndrome? Brain Dev 1992;14:342e5.
Connolly AM, Chez MG, Pestronk A, Arnold ST, Mehta S, Deuel RK. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr 1999;134:607e13.
Mikati MA, Saab R, Fayad MN, Choueiri RN. Efficacy of intravenous immunoglobulin in Landau-Kleffner syndrome. Pediatr Neurol 2002;26: 298e300.
Kramer U, Chi CS, Lin KL, et al. Febrile infection-related epilepsy syndrome (FIRES): Pathogenesis, treatment, and outcome: A multicenter study on 77 children. Epilepsia 2011;52:1956e65.
Specchio N, Fusco L, Claps D, Vigevano F. Epileptic encephalopathy in children possibly related to immune-mediated pathogenesis. Brain Dev 2010;32:51e6.
Ariizumi M, Baba K, Hibio S, et al. Immunoglobulin therapy in the West syndrome. Brain Dev 1987;9:422e5.
Espinosa Zacarías J, Gutiérrez Moctezuma J, Villegas Peña H, Olmos De Alba G. Intravenous treatment with immunoglobulins in epileptic syndromes which are difficult to control. Rev Neurol 2002;34:816e9.
Echenne B, Dulac O, Parayre-Chanez MJ, et al. Treatment of infantile spasms with intravenous gamma-globulins. Brain Dev 1991;13:313e9.
Montelli TC, Mota NG, Peraçoli MT, Torres EA, Rezkallah-Iwasso MT. Immuno- logic disturbance in West and Lennox-Gastaut syndromes. Arq Neuropsiquiatr 1984;42:132e9.
Montelli TC, Soares AM, Peraçoli MT. Immunologic aspects of West syndrome and evidence of plasma inhibitory effects on T cell function. Arq Neuro- psiquiatr 2003;61:731e7.
Illum N, Taudorf K, Heilmann C, et al. Intravenous immunoglobulin: A single- blind trial in children with Lennox-Gastaut syndrome. Neuropediatrics 1990;21:87e90.
Van Rijckervorsel-Harmant K, Delire M, Rucquoy-Ponsar M. Treatment of idiopathic West and Lennox-Gastaut syndromes by intravenous administra- tion of human polyvalent immunoglobulins. Eur Arch Psychiatry Neurol Sci 1986;236:119e22.
Gross-Tsur V, Shalev RS, Kazir E, Engelhard D, Amir N. Intravenous high-dose gammaglobulins for intractable childhood epilepsy. Acta Neurol Scand 1993;88:204e9.
Etzioni A, Jaffe M, Pollack S, Zelnik N, Benderly A, Tal Y. High dose intravenous gamma-globulin in intractable epilepsy of childhood. Eur J Pediatr 1991;150: 681e3.
van Engelen BG, Renier WO, Weemaes CM, Strengers PF, Bernsen PJ, Notermans SL. High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome: An add-on study. Eur J Pediatr 1994;153:762e9.
Kramer U, Sagi L, Goldberg-Stern H, Zelnik N, Nissenkorn A, Ben-Zeev B. Clinical spectrum, and medical treatment of children with electrical status epilepticus in sleep (ESES). Epilepsia 2009;50:1517e24.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
